I have rec'd the order, and was pleased with every aspect of the order. I do look
forward to ordering in the future, so could you please keep in contact with me via
this email.
Experts Offer Guidance on Use of DAAs for Difficult-To-Treat Hep C Patients - Gastroenterology & Endoscopy News
Gastroenterology & Endoscopy NewsExperts Offer Guidance on Use of DAAs for Difficult-To-Treat Hep C PatientsGastroenterology & Endoscopy Newsby Christina Frangou San Francisco—For several months, it has been one of the most pressing questions among clinicians who treat patients with hepatitis C: How well do the two FDA-approved direct-acting antivirals (DAAs) perform in the patients who .
New Antivirals Show Poor Safety in HCV With Cirrhosis - Medscape
New Antivirals Show Poor Safety in HCV With CirrhosisMedscapeMay 2, 2012 (Barcelona, Spain) — Two relatively new direct-acting antiviral drugs have poor safety profiles in patients with hepatitis C virus (HCV) and cirrhosis, including a high rate of serious adverse events leading to study discontinuation.
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs ... - MarketWatch (press release)
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs .
AIDS Fight Enters New Phase with Prevention Pill - Pharmaceutical Processing
Boston.
FDA advisory panel endorses HIV pill for healthy people - The Seattle Times
